Skip to main content
. Author manuscript; available in PMC: 2011 Aug 23.
Published in final edited form as: Curr Opin Rheumatol. 2010 Jul;22(4):397–403. doi: 10.1097/BOR.0b013e32833ac7fe

Figure 2.

Figure 2

Example drug exposure and adherence for a hypothetical patient.

A. Truth: dark solid lines=true consumption

B. Claims data “raw”: dark solid lines=drug use identified through pharmacy claims, dotted line=days in hospital identified through medical claims.

C. Claims data “raw” +50% days supplied grace period: dark solid lines=drug use identified through raw pharmacy claims, light solid lines=coverage added by applying a maximum 50% days supplied grace period to all gaps, dotted line=days in hospital identified through medical claims.

t0=start of observation period, t1=end of observation period; calculations only consider drug coverage during the observation period